on Marinomed Biotech AG
Marinomed Biotech AG Secures EUR 2.5 Million Convertible Bond Agreement
On September 1, 2025, Marinomed Biotech AG announced an agreement with a German investor to issue a secured EUR 2.5 million convertible bond. This financial move comes as the company explores new financing strategies. The bond, with a 12-month term extendable to 24 months, is set to carry an 8.5% interest payable at maturity.
Crucially, the bond offers conversion rights to company shares, with a conversion rate set at EUR 15 per share, translating to up to 166,666 shares. However, this issuance is contingent on approval from an upcoming extraordinary shareholders meeting and requires specific corporate resolutions.
The bond's issuance excludes existing shareholders' subscription rights, focusing exclusively on the new investor. Marinomed is actively evaluating alternative financing options to bolster its financial positioning.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Marinomed Biotech AG news